CLARIVATE PLC — Form 8-K
Filed October 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Clarivate completed the sale of its Life Sciences & Healthcare segment to Altaris LLC for $600 million on October 6, 2026, as previously announced July 6, 2026. The company will use proceeds to reduce debt and strengthen its balance sheet. Post-divestiture, Clarivate focuses on two segments: Academia & Government (Web of Science, ProQuest, Alma, Vega) and Intellectual Property (IPOne, Derwent, CompuMark, IPfolio).
Why this rating
Sale represents ~46% of $1.3B market cap—a major portfolio simplification. Strengthens balance sheet and refocuses strategy. Material but not transformational; execution risk remains on debt reduction and growth in remaining segments.
Tradability signal
NO TRADE
No trade: positive news with only +2.3% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: +0.03% over 4 hrs, n=201). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $1.45 ▼ 1.36% | at our read · unknown $1.47 | +10 min · unknown $1.46 ▼ 0.68% | +30 min · unknown $1.45 ▼ 1.36% | +1 hr · unknown $1.44 ▼ 2.38% | +4 hrs · unknown $1.47 ▲ 0.00% |
The stock had already moved +1.38% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.